Medical devices in cardiology. Arterial closure.
Employees: 18
Market regions:
USA, Europe
Overview
CardioDex is a privately owned company engaged in the
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
development, manufacturing, and marketing of devices for arterial
access site closure, following catheterization procedures.
CardioDex offers the interventional cardiologists closure
technologies that provide an extremely high success rate, under 2
minute deployment, and high cath-lab throughput, resulting in
high cath-lab utilization and profit maximization.
The Company was founded by one of the most renowned medical
entrepreneurs in Israel, Dr. Shimon Eckhouse, a scientist who
enjoys vast experience and international successes.
CardioDex has developed state-of-the-art disposable devices;
Epiclose and Epiclose Plus. The company's flagship product, the
EpiClose Plus overcomes the limitations that cardiologists,
cath-labs and patients are currently confronted with, in an
unprecedented manner CardioDex's products do not use any glue,
collagen, suturing or other foreign materials that might promote
a clinical reaction, and do not deposit any residual material in
the patient's body. In addition, the products do not require
exchange of the introducer sheath, and permit re-access to the
artery should a non-deployment occur.
CardioDex's products expedite arterial closure through
hemostasis. The process relies on familiar balloon
inflation/deflation techniques, which apply selective pressure
precisely over the puncture site. The products do not require
exchange of the introducer sheath.
CardioDex's products address both the diagnostic and therapeutic
markets.
The Company has an ISO 9001 and EN 13485:2003 approved
manufacturing facility, and CE certification for the
manufacturing of its EpiClose product.
The Company enjoys a rich intellectual property portfolio and a
strong and concrete IP coverage for it's as current and future
technology applications.
